Abstract: AIM : To review the therapeutical effect of trimetazidine and shexiang baoxin pill on chronic heart failure.METHODS: The literature of randomized and controlled trialls(RCT) about treatment of chronic heart failure with trimetazidine and shexiang baoxin pill were retrieved from Cochrane Library, ProQuest Central, MEDLINE, EMbase, PEDro, OpenSIGLE, NTIS, ScienceDirect, CNKI, VIP, Wanfang Data and CBM(by Apri 30, 2013), and then 2 reviews independently chose RCT , extracted materials, checked crossly and gave methodological quality evaluation. Meta analysis was conducted by using Revman 5.2 software.RESULTS:A total of 7 trials and 451 patients were discovered .Meta-analyses showed that at the end of the study , compared with routine remedy alone, the extra remedy of trimetazidine and shexiang baoxin pill on chronic heart failure got abvious amelioration on the improvement of clinical efficacy, left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter(LVEDD), left ventricular end diastolic volume(LVEDV) and the walking range of 6 minutes [WMD=(95%CI)3.09(2.07, 4.59), WMD=(95%CI)5.81(4.69 to 6.93), WMD=-5.31(-7.19 to -3.43), WMD=-4.6(-8.59 to -0.64)], WMD=42.73(32.48 to 52.97).CONCLUSION: The existing evidence shows that the therapy of trimetazidine and shexiang baoxin pill is effective to on chronic heart failure and can ameliorate clinical efficacy , left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter(LVEDD), left ventricular end diastolic volume(LVEDV) and the walking range of 6 minutes. There were not any adverse reactions .As the limitation of the quality of enclosed literature, the review on the curative effect of chronic heart failure expects more randomized controlled double-blin-ded trials with high quality.

Key words: trimetazidine, shexiang baoxin pill, chronic heart failure, meta-analysis